BioSight Ltd.

4 clinical trials · Sponsor

Record	Firm	Date
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML (NCT05503355)	BioSight Ltd.	2022-08-17
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS (NCT04749355)	BioSight Ltd.	2021-11-14
Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy (NCT03435848)	BioSight Ltd.	2018-08-14

Every clearance here is in the API, with alerts when new ones post.